134 related articles for article (PubMed ID: 24114194)
1. Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
Tanaka M; Hashimoto Y; Sekiya N; Honda N; Deacon S; Yamamoto M
J Bone Miner Metab; 2014 Jul; 32(4):447-54. PubMed ID: 24114194
[TBL] [Abstract][Full Text] [Related]
2. An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women.
Tanaka M; Hashimoto Y; Hasegawa C
Bone; 2015 Dec; 81():178-185. PubMed ID: 26188109
[TBL] [Abstract][Full Text] [Related]
3. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.
Nagase S; Hashimoto Y; Small M; Ohyama M; Kuwayama T; Deacon S
Br J Clin Pharmacol; 2012 Dec; 74(6):959-70. PubMed ID: 22533981
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
Hasegawa C; Ohno T; Umemura T; Honda N; Ohyama M; Nagase S; Small M; Deacon S; Ogawa M; Ieiri I
J Clin Pharmacol; 2014 Jan; 54(1):23-34. PubMed ID: 24115072
[TBL] [Abstract][Full Text] [Related]
5. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Eastell R; Dijk DJ; Small M; Greenwood A; Sharpe J; Yamada H; Yuba M; Tanimoto M; Deacon S
Osteoporos Int; 2016 Jan; 27(1):309-18. PubMed ID: 26446770
[TBL] [Abstract][Full Text] [Related]
6. Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Nagase S; Ohyama M; Hashimoto Y; Small M; Sharpe J; Manako J; Kuwayama T; Deacon S
J Bone Miner Metab; 2015 Jan; 33(1):93-100. PubMed ID: 24458199
[TBL] [Abstract][Full Text] [Related]
7. Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.
Hasegawa C; Kastrissios H; Monteleone J; Ohno T; Umemura T; Ohyama M; Nagase S; Small M; Deacon S; Ogawa M; Ieiri I
J Clin Pharmacol; 2014 Aug; 54(8):937-48. PubMed ID: 24615681
[TBL] [Abstract][Full Text] [Related]
8. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
Tanaka M; Hashimoto Y; Hasegawa C; Deacon S; Eastell R
BMC Musculoskelet Disord; 2017 Jun; 18(1):267. PubMed ID: 28629344
[TBL] [Abstract][Full Text] [Related]
9. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Stoch SA; Zajic S; Stone JA; Miller DL; van Bortel L; Lasseter KC; Pramanik B; Cilissen C; Liu Q; Liu L; Scott BB; Panebianco D; Ding Y; Gottesdiener K; Wagner JA
Br J Clin Pharmacol; 2013 May; 75(5):1240-54. PubMed ID: 23013236
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study.
Eastell R; Nagase S; Ohyama M; Small M; Sawyer J; Boonen S; Spector T; Kuwayama T; Deacon S
J Bone Miner Res; 2011 Jun; 26(6):1303-12. PubMed ID: 21312264
[TBL] [Abstract][Full Text] [Related]
11. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2011 Dec; 49(6):1351-6. PubMed ID: 21982869
[TBL] [Abstract][Full Text] [Related]
12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
13. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2014 Aug; 65():1-8. PubMed ID: 24784023
[TBL] [Abstract][Full Text] [Related]
14. ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.
Ochi Y; Yamada H; Mori H; Kawada N; Kayasuga R; Nakanishi Y; Tanaka M; Imagawa A; Ohmoto K; Kawabata K
J Bone Miner Metab; 2014 Nov; 32(6):645-52. PubMed ID: 24317478
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Nagase S; Ohyama M; Hashimoto Y; Small M; Kuwayama T; Deacon S
J Clin Pharmacol; 2012 Mar; 52(3):306-18. PubMed ID: 21719717
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cathepsin K for treatment of osteoporosis.
Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
[TBL] [Abstract][Full Text] [Related]
17. [Cathepsin K antagonists: preclinical and clinical data].
Gamsjäger M; Resch H
Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
